Prognostic significance of radiodensity-based skeletal muscle quantification using preoperative CT in resected non-small cell lung cancer

Eun Young Kim; Young Jae Kim; Young Saing Kim; Kun Woo Kim; Ji Young Jeon; Kwang Gi Kim

doi:10.21037/jtd-20-2344

Prognostic significance of radiodensity-based skeletal muscle quantification using preoperative CT in resected non-small cell lung cancer

J Thorac Dis. 2021 Feb;13(2):754-761. doi: 10.21037/jtd-20-2344.

Authors

Eun Young Kim¹, Young Jae Kim², Young Saing Kim³, Kun Woo Kim⁴, Ji Young Jeon¹, Kwang Gi Kim²

Affiliations

¹ Department of Radiology, Gil Medical Center, Gachon University College of Medicine, Incheon, Korea.
² Department of Biomedical Engineering, Gachon University College of Medicine, Incheon, Korea.
³ Department of Internal medicine, Gil Medical Center, Gachon University College of Medicine, Incheon, Korea.
⁴ Department of Thoracic and Cardiovascular Surgery, Gil Medical Center, Gachon University College of Medicine, Incheon, Korea.

Abstract

Background: Sarcopenia is associated with poor prognosis in lung cancer. Skeletal muscle area can be quantified based on radiodensity of CT scan. The purpose of this study was to evaluate the prognostic significance of radiodensity-based detailed skeletal muscle quantification on outcomes after surgery of non-small cell lung cancer (NSCLC).

Methods: Single cross-sectional area of the skeletal muscle (-29 to 150 HU) at the 3rd lumbar vertebra (L3) level retrospectively measured on preoperative CT for NSCLC patients (n=272), who underwent surgical resection during 2011 to 2016. The diagnosis of sarcopenia was made when a L3 muscle index (L3MI; L3 muscle area/height2) of less than 55 cm²/m² for men and less than 39 cm²/m² for women. Skeletal muscle was subsequently classified based on radiodensity level as low attenuation muscle (-29 to <30 HU) and high attenuation muscle (30 to 150 HU). Using a maximal-chi-squared test, low attenuation muscle accounted less than 24.5% of the total muscle, which was considered healthy muscle. Data on clinical characteristics (demographic information, TNM stage, histology) and prognosis (disease-free survival; DFS, and overall survival; OS) were collected.

Results: Sarcopenia was found 22.4% in preoperative CT (32.9% for men and 6.5% for women). The prevalence of patients with healthy muscle was 15.4% (21.3% for men and 6.5% for women). There was no significant difference between the 3-year DFS rate (77.0% vs. 67.0%, P=0.142) or 3-year OS rate (84.8% vs. 87.9%, P=0.576) between patients with and without sarcopenia. However, patients with healthy muscle tend to show longer 3-year DFS rate (79.4% vs. 67.2%, P=0.094) and 3-year OS rate (92.6% vs. 86.1%, P=0.176). In the multivariable analysis, healthy muscle was one of the independent prognosticators for a 3-year DFS rate (HR, 0.50, P=0.035), along with R1 resection (HR, 5.90, P<0.001), pathologic T stage (HR, 2.69, P<0.001), and pathologic N stage (HR, 2.43, P<0.001).

Conclusions: The proportion of low attenuation muscle was associated with DFS in resected lung cancer patients. Further investigation is needed to establish whether radiodensity-based detailed skeletal muscle quantification could be early biomarker to predict prognosis in NSCLC.

Keywords: Skeletal muscle; X-ray computed; non-small cell lung cancer (NSCLC); prognostic factor; radiodensity; sarcopenia; surgery; tomography.